Clinical trials: Breast Cancer, Metastatic Breast Cancer
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Breast Cancer Metastatic
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Background: Endocrine therapy is an effective and safe treatment for hormone receptor positive breast cancer. Unfortunately , endocrine treatment resistance occurs and there is an urgent need for treatment alternative.
- Trial name
- NCT03045653
- Testing
- Tamoxifen Oral Product
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Non-Metastatic Breast Cancer
Effectiveness of Original vs. AI-Generated Plain Language Summaries of Systematic Reviews
The study explores how patients with non-metastatic breast cancer perceive and comprehend original Plain Language Summary and AI-generated Plain Language Summary (PLS) of two systematic reviews from the Cochrane Library.
- Trial name
- NCT07140107
- Testing
- AI-generated PLS, Original PLS
- Where
- Croatia
- Volunteers
- 130 people
- Sponsor
- University of Split, School of Medicine
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Breast Cancer
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer
This is a phase II trial of Doxil on day 1 and vinorelbine on days 1 and 2 in women with metastatic breast cancer. Administered every 28 days.
- Trial name
- NCT00159094
- Testing
- Doxil and Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hematology Oncology Consultants
Breast Cancer
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
- Trial name
- NCT03393845
- Testing
- Pembrolizumab, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Nancy Chan, MD
Breast Neoplasms
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been…
- Trial name
- NCT00191672
- Testing
- Gemcitabine, Paclitaxel, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Metastatic Breast Cancer
Polymorphism Interaction to Predict Bevacizumab Efficacy
Although many attempts have been done to identify vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms (SNPs) correlated with bevacizumab response, in advanced cancer patients, the results are still…
- Trial name
- BEVAGENE (NCT01935102)
- Where
- Italy
- Volunteers
- 169 people
- Sponsor
- University of Pisa
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer.
- Trial name
- NCT01661153
- Where
- 2 sites in Croatia
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00014430
- Testing
- trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
HER2-positive Breast Cancer
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced, unresectable, or metastatic…
- Trial name
- NCT03125928
- Testing
- Atezolizumab, Paclitaxel, Trastuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Brain Metastases
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and pyrotinib with fulvestrant in ER/PR positive and HER2-positive breast cancer patients with brain metastasis.
- Trial name
- NCT04334330
- Testing
- Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs.
- Trial name
- NCT00003253
- Testing
- paclitaxel, antitumor drug screening assay
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oncotech
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with…
- Trial name
- SOPHIA (NCT02492711)
- Testing
- Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
- Where
- 167 sites in United States, Austria and 16 more
- Volunteers
- 624 people
- Sponsor
- MacroGenics
Breast Cancer
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
This is an open-label, mono-center phase I/II study designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated…
- Trial name
- NCT00930475
- Testing
- RAD001 (Everolimus) in combination with carboplatin
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Charite University, Berlin, Germany
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
Breast Cancer
Efficacy and Safety of 500mg of Fulvestrant
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness.
- Trial name
- NCT00585507
- Testing
- Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Breast Cancer
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
Patients with locally advanced or metastatic breast cancer and with measurable primary breast tumor will be treated with 70mg docetaxel combined with ketoconazole.
- Trial name
- NCT00212095
- Testing
- docetaxel and ketoconazole
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer Metastatic
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
This is a multicenter, prospective, randomized, open-label, controlled phase II study to test the addition of the CDK4/6 inhibitor ribociclib to anti-hormonal treatment as maintenance therapy in patients with disease control (at…
- Trial name
- AMICA (NCT03555877)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- Germany
- Volunteers
- 56 people
- Sponsor
- GBG Forschungs GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.